Peptide therapy clinic marketing: claims and ads

A clinic that prescribes a peptide with no FDA approved product behind it is prescribing a compounded drug. Whether a pharmacy may compound that peptide at all depends on where its ingredient sits in a federal framework of monographs, approved drug components, a regulatory list and a set of FDA categories that change during the year. That framework decides what a clinic can responsibly put on a menu, and the FTC Act and ad platform policies decide how the clinic can talk about it.

This guide covers what is specific to peptides. The difference between 503A pharmacies and 503B outsourcing facilities, the claims FDA has warned about, copies of commercially available drugs and naming the compounder are covered in our guide to compounding pharmacy marketing, so they are not repeated here. Compounded GLP-1 drugs are covered in weight loss clinic marketing, and drip menus in IV therapy clinic marketing.

This is general information, not legal or medical advice. Sources cited were checked on October 29, 2026: 21 U.S.C. 353a(b)(1)(A) (section 503A); FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026); FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list updated May 14, 2026); FDA, Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B (content current as of April 22, 2026); FDA guidance, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (January 7, 2025); 21 CFR 216.23 and 600.3(h); 15 U.S.C. 45 and 52; the FTC Health Products Compliance Guidance; and the Google Ads Healthcare and medicines, Unapproved substances, and Speculative and experimental medical treatment policies. FDA moves substances between categories, so check the current lists on the day a page or ad goes live. Have a health care attorney review your menu, claims and programs.

Where a peptide ingredient fits under section 503A

Section 503A of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 353a, lets a licensed pharmacist or physician compound for an identified patient on a valid prescription without meeting the new drug approval requirements, but only under conditions. One condition is about the ingredient. Under 353a(b)(1)(A)(i), the bulk drug substances used must either comply with an applicable United States Pharmacopoeia or National Formulary monograph, if one exists, and the USP chapter on pharmacy compounding; or, if no monograph exists, be components of drugs approved by FDA; or, if neither is true, appear on a list FDA develops through regulations. The same paragraph requires that the substances be made by an establishment registered with FDA and come with valid certificates of analysis.

The list FDA has issued so far is at 21 CFR 216.23. Paragraph (a) names six substances that can be used under the third route, and none of the six is a peptide. Paragraph (b) names four substances FDA decided not to include. FDA’s page on bulk drug substances under 503A says the agency proposed further additions in September 2019 and will issue a final regulation after considering comments, and that it continues to evaluate nominated substances on a rolling basis through notice and comment rulemaking.

So for a peptide that has no monograph and is not a component of an approved drug, the statute’s third route is not open today. What remains is FDA’s interim policy, which describes when the agency does not intend to take action while it builds the list. That policy is where the categories come in.

FDA’s three categories, as of May 14, 2026

FDA’s interim policy sorts nominated bulk drug substances into three categories. Its page on bulk drug substances under 503A, current as of May 14, 2026, describes them this way:

Category 1: substances that may be eligible for the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list. FDA does not intend to take action against a compounder for using them, provided the conditions in its guidance are met.
Category 2: substances nominated with sufficient information, where FDA has identified significant safety risks relating to their use in compounding pending further evaluation. FDA says it would consider taking action against a compounder using them under its general enforcement policies.
Category 3: substances nominated with insufficient supporting information for FDA to evaluate them. They are not eligible for the category 1 policy, and FDA would consider taking action under its general enforcement policies.

The January 2025 guidance spells out the category 1 conditions. The substance must appear in category 1 on FDA’s website; the original manufacturer and every later manufacturer of the bulk substance must be registered with FDA; the substance must come with a valid certificate of analysis; and the compounded drug must meet all other conditions of section 503A. The guidance also says FDA does not intend to place substances nominated on or after January 7, 2025 into any category, so those substances are outside the interim policy, as are substances that a final rule has already included on, or kept off, the list.

FDA’s category 2 page lists peptides among the substances it says raise significant safety risks, with the date each was added. For peptides, the risks FDA describes include the potential for immunogenicity due to aggregation and peptide-related impurities, complexities in characterizing the active ingredient, and, for several of them, no or only limited safety information, so that FDA lacks sufficient information to know whether the drug would cause harm. The same page has a second table of substances that were previously in category 2 and were withdrawn by their nominators, and several peptides appear there too. The interim policy covers substances that appear in category 1, and a withdrawn nomination does not put a substance there.

Status can change by route of administration and within weeks. The category list updated May 14, 2026 records that one peptide was removed from category 1 on April 22, 2026 because its nominations were withdrawn, and that it will be added back for routes other than injection after a nominator clarified that it meant to withdraw only the injectable route. FDA also announced that it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about that substance. A menu written in March would have been out of date in April and again in May.

Peptide or protein: the 40 amino acid line

FDA’s regulation at 21 CFR 600.3(h) defines a biological product to include a protein, and paragraph (h)(6) defines a protein as any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. A chain at or below that size is outside that definition. A longer one falls within it, and the compounding exemptions discussed above are written for drugs, so ask your pharmacy and counsel which framework applies before a product above that line appears on any page.

What the menu and the ads can say

Start with what a peptide offering is: a prescription drug compounded for an identified patient after a clinician’s evaluation, made with an ingredient whose regulatory status you have checked on a stated date. Everything on the menu should be consistent with that.

Never call a compounded peptide FDA approved. 21 CFR 216.23(d) says that, based on evidence currently available, there are inadequate data to demonstrate the safety or efficacy of any drug compounded from the substances on the 503A list, and that anyone who represents such a drug as FDA approved, or otherwise endorsed by FDA generally or for a particular indication, will cause it to be misbranded. If that is true for substances FDA has placed on its list, it applies with more force to substances it has not. Words such as “FDA registered pharmacy” need the same care; our compounding guide explains why registered is not approved. Clinics that also offer compounded hormones should see our guide to hormone pellet therapy marketing.

Leave out outcome claims you cannot support with the evidence the law expects. Section 12 of the FTC Act, 15 U.S.C. 52, makes it unlawful to disseminate a false advertisement likely to induce the purchase of drugs or services, and section 5, 15 U.S.C. 45, prohibits deceptive acts or practices. The FTC Health Products Compliance Guidance says health benefit claims need competent and reliable scientific evidence, and that randomized, controlled human clinical trials are the most reliable form of evidence and are generally the type of substantiation experts would require for health benefit claims. Recovery, healing, longevity, anti-aging, fat loss, muscle gain, sleep and cognition promises are all health benefit claims. So is an image of a before and after body, and so is a testimonial; our guide to patient testimonials and before-and-after photos covers both.

Do not call a peptide safe. FDA’s category 2 page says, for several peptides, that the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. A safety claim that FDA itself says it cannot make is a claim the clinic would have to prove on its own.

Keep doses, cycles and protocols off marketing pages. Section 503A is built around a prescription for an identified patient, and the decision belongs to the prescriber after evaluating that patient. The same goes for packages that pair a fixed number of vials with a promised outcome.

Name who compounds the drug. The compounding guide explains why branding that implies the clinic is the compounder is one of the claims FDA has warned about. Keep the pharmacy’s written confirmation of each substance’s category, route and the date checked in your files, next to the page that mentions it.

If the program runs through telehealth, licensure by patient location, health data tracking and the other points in our guide to telehealth marketing apply as well.

Clinics that present peptides as part of a longevity or anti-aging program also make lifespan and biological age claims; those are covered in our longevity clinic marketing guide.

Google Ads and peptide therapy

Google’s Healthcare and medicines policy restricts the promotion of services related to the online prescribing, dispensing and sale of prescription drugs, and a compounded peptide under 503A is dispensed on a prescription. An offer that includes online prescribing or shipping comes under those rules, which our healthcare ad policy basics guide summarizes.

Google’s Unapproved substances policy says Google does not allow the promotion of certain products, regardless of any claims of legality. The policy names, among others:

All items on a non-exhaustive list of unapproved pharmaceuticals and supplements that the policy links to.
Products that imply they are as effective as prescription drugs or controlled substances.
Non-government approved products marketed in a way that implies they are safe or effective for use in preventing, curing or treating a particular disease or ailment.
Products that have been subject to any government or regulatory action or warning.
Products with names that are confusingly similar to an unapproved pharmaceutical or supplement or controlled substance.

The policy page says violations will not lead to immediate account suspension without prior warning, and that Google will issue a warning at least 7 days before suspending an account. Check every substance named in an ad, a keyword or the landing page against the list the policy links to and against FDA’s category 2 page before the campaign runs.

A separate section of the Healthcare and medicines policy says that the promotion of speculative and experimental medical treatments is not allowed. Campaigns that promote the clinic, its clinicians and a consultation, without naming substances or promising results, leave the decision about any drug to the visit, where it belongs. The landing page is still reviewed, so the menu behind the ad has to meet the same standard.

Illustration: rewriting a peptide therapy menu

Illustration: a wellness clinic’s peptide page lists eight peptides by name, each with an injection icon, under the headline “FDA-approved peptides for faster recovery and longer life.” Each card promises a result, lists a weekly dose and a 12 week cycle, and calls the peptide safe and natural. A paid search campaign bids on the names of several of the eight.

The clinic asks its compounding pharmacy, in writing, for the category and route status of each substance as of that week, and checks the answers against FDA’s lists. One substance appears in category 2. Two appear only in the table of withdrawn nominations. One is in category 1 for routes other than injection, and the clinic had listed it as an injection. The rewritten page drops those four, removes “FDA-approved”, “safe” and “natural”, the result promises, the doses and the cycles, and names the compounding pharmacy. It says that any compounded drug is prescribed only after a clinician’s evaluation, that compounded drugs are not FDA approved, and on what date the clinic last checked the status of each substance it lists. The campaign now bids on consultation terms and the clinic’s name, not substance names. Counsel reviews the page and the ads before either goes live.

Checklist

Each substance on the menu checked against 21 U.S.C. 353a(b)(1)(A)(i), 21 CFR 216.23 and FDA’s current category lists, with the date checked recorded.
Nothing in category 2, category 3, the withdrawn nominations table or nominated on or after January 7, 2025 offered as if it were within FDA’s interim policy.
Route of administration on the menu matches the route FDA’s category listing covers.
Anything above 40 amino acids reviewed by counsel before it appears on a page (21 CFR 600.3(h)(6)).
No “FDA approved” or FDA endorsed wording for any compounded peptide (21 CFR 216.23(d)).
No outcome, safety or “natural” claims without competent and reliable scientific evidence (15 U.S.C. 45, 52; FTC Health Products Compliance Guidance).
No doses, cycles or protocols on marketing pages; prescribing stays with the clinician.
The compounding pharmacy is named, and its written confirmation of each substance’s status is on file.
Ads, keywords and landing pages checked against Google’s Unapproved substances and Healthcare and medicines policies before launch.
Testimonials and before-and-after images reviewed as our testimonials guide describes.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices. For a clinic that offers peptide therapy, we can build a service page on your medical website that describes the consultation, the clinician’s role and the regulatory status of what you offer in plain words, with a dated status note you update from your pharmacy’s written confirmation, and run campaigns built around consultations rather than substance names. We do not decide which substances you may offer; that is for your pharmacy, your clinicians and your attorney. Our AI front desk is built with HIPAA in mind and can answer questions about hours, locations and booking from a list you approve, passing clinical questions to your staff. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We do not sell lead lists and do not pay for referrals. For the wider set of rules we follow, see our healthcare marketing rules hub.

Can a compounding pharmacy make any peptide a clinic asks for?

Not under section 503A. 21 U.S.C. 353a(b)(1)(A)(i) requires a bulk drug substance to meet a USP or NF monograph, be a component of an FDA approved drug, or appear on FDA’s list at 21 CFR 216.23. For other nominated substances, FDA’s interim policy describes when it does not intend to take action, and that policy covers substances in category 1 that meet its conditions.

What does category 2 mean for a peptide?

FDA places a substance in category 2 when it has identified significant safety risks relating to its use in compounding pending further evaluation. FDA says it would consider taking action against a compounder using a category 2 substance under its general enforcement policies, and it publishes the risks it identified on its category 2 page.

Can we say our peptides are FDA approved?

No. 21 CFR 216.23(d) says representing a drug compounded from a substance on the 503A list as FDA approved, or otherwise endorsed by FDA, will cause it to be misbranded. Substances not on that list have no stronger footing.

How often should we check a substance’s status?

Before each page or ad goes live and whenever FDA updates its lists. The category list updated May 14, 2026 shows a substance removed from category 1 in April 2026 and added back for non-injectable routes in May 2026.

Can we run Google Ads for peptide therapy?

Google’s Unapproved substances policy bars promotion of items on its linked list of unapproved pharmaceuticals and supplements, products subject to any government or regulatory action or warning, and products marketed as safe or effective for a disease without government approval. Prescription drug services and speculative treatment rules also apply. Ads for the clinic and a consultation are a different matter from ads for a substance.

Can we post patient results from peptide therapy?

A result shown in a testimonial or photo is a health benefit claim. The FTC Health Products Compliance Guidance says such claims need competent and reliable scientific evidence, and that randomized, controlled human clinical trials are generally the type experts would require.

Sources

More in Cash-pay, aesthetic and wellness care

Peptide therapy clinic marketing: FDA bulk substance categories, claims and ad rules